# How Long Does It Take for a GLP-1 to Work? What Tirzepatide Data Show

See what two tirzepatide trials found about weight change at weeks 8 and 72, and how those results compare with an observational study.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/how-long-does-it-take-for-a-glp1-to-work
Updated: 2026-11-14
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# How Long Does It Take for a GLP-1 to Work? What Tirzepatide Data Show

Trial participants who had not lost 5% of body weight by week 8 still reached a clinically meaningful result by week 72 — a significantly smaller one. In routine care the twelve-month mean was -5.9% on semaglutide.

Editorial profile: [Wesley Jenkins](https://buythisglp.com/authors/wesley-jenkins)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20269 min readUpdated November 2026

Sorted at week 8, followed to week 72 · week 8 · week 72 · lost ≥5% by week 8 · lost <5% by week 8 · Study design · Illustrative · trajectories

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   The tirzepatide analysis defined early response as losing at least 5% of body weight by week 8.
-   Participants who missed that mark still reached a clinically meaningful result by week 72, and a smaller one.
-   The two groups had broadly similar patterns of gastrointestinal side effects.
-   In routine care the twelve-month mean was -13.0% on tirzepatide and -5.9% on semaglutide across 14,046 adults.
-   A separate observational study grouped 135,349 patients by weight change across four brands.

A post hoc analysis of 2,384 tirzepatide-treated trial participants split them at week 8 by whether they had lost 5% of their body weight [\[1\]](https://buythisglp.com/research/how-long-does-it-take-for-a-glp1-to-work#ref-1). Those who had not still reached a clinically meaningful result by week 72. Theirs was significantly smaller than the early responders’.

If your weight has changed little after two months, the guide to [why weight loss varies](https://buythisglp.com/research/why-do-some-people-not-lose-weight-on-a-glp1) covers factors you can discuss with your prescriber. The analysis below follows people who started tirzepatide in two specific trials.

## What was analyzed

Researchers took the tirzepatide-treated participants from the two SURMOUNT trials and sorted them by their week-8 result. That is 1,775 from the trial in people without type 2 diabetes and 609 from the trial in people with it, 2,384 in total. [\[1\]](https://buythisglp.com/research/how-long-does-it-take-for-a-glp1-to-work#ref-1) Those who had lost at least 5% of their body weight by then were classed as early responders; those who had not were not. Both groups were then followed to week 72.

Early responders differed from the rest at baseline: they were more likely to be female, more likely to be White, and had lower starting HbA1c. That matters for how to read everything that follows, because nobody was assigned to a group. People sorted themselves by how their own bodies behaved.

## What happened by week 72

Both groups achieved clinically meaningful weight reduction and improvements in cardiometabolic risk parameters including HbA1c. The early responders did significantly better on both.

At week 72, estimated mean weight loss was 23.3% for early responders and 14.6% for the other group in SURMOUNT-1. In SURMOUNT-2, which enrolled adults with type 2 diabetes, the estimates were 20.0% and 10.8%, respectively[\[1\]](https://buythisglp.com/research/how-long-does-it-take-for-a-glp1-to-work#ref-1). These are group averages.

What the analysis does not license

It does not say “keep paying, it will come good” — early non-responders ended up worse off than early responders, and that gap was significant. It also does not say “stop now and save your money” — early non-responders still reached a clinically meaningful result by week 72. Both readings are available and neither is what the analysis shows. What it shows is that week 8 carries real information and is not a verdict.

## What a year looks like outside a trial

A separate cohort of 14,046 US adults with a BMI of 30 or more measured mean twelve-month weight change in routine care[\[2\]](https://buythisglp.com/research/how-long-does-it-take-for-a-glp1-to-work#ref-2). It came to -13.0% on tirzepatide, -5.9% on semaglutide, and roughly -4.0% each on exenatide, dulaglutide and liraglutide. The observational design leaves room for differences between treatment groups.

The [review of semaglutide outcomes in routine care](https://buythisglp.com/research/outside-the-trial-semaglutide-managed-six-percent) explains why a clinic cohort and a trial can report different averages. If you are weighing the expense, the [monthly price guide](https://buythisglp.com/research/how-much-does-a-glp1-cost-per-month) explains what published quotes cover. The study did not measure the cost of treatment.

## How wide the spread is

A separate analysis grouped 135,349 patients by weight change[\[3\]](https://buythisglp.com/research/how-long-does-it-take-for-a-glp1-to-work#ref-3). The share who lost more than 15% ranged from 10% among Ozempic users to 34% among Zepbound users in this cohort.

Those four brands contain two active ingredients. Prescribing indications, doses and patient characteristics can differ by brand. The [analysis of brand differences](https://buythisglp.com/research/super-responders-and-the-brand-confound) explains why these observational rates cannot isolate the effect of the product. Individual outcomes varied within each group.

## The tolerability finding is the useful one

Gastrointestinal side effects had similar patterns, severity and timing in the two groups[\[1\]](https://buythisglp.com/research/how-long-does-it-take-for-a-glp1-to-work#ref-1). The researchers compared groups defined by early weight change.

The [guide to GLP-1 side effects](https://buythisglp.com/research/what-are-the-side-effects-of-a-glp1) explains what patients may experience. In this analysis, similar patterns across groups did not establish whether one person’s nausea predicted their weight change.

## What this cannot tell you

Whether becoming an early responder would help. Nobody was made into one. The comparison is between two groups of people who differed before the drug started and continued to differ after, so it describes prognosis rather than cause.

There is also no placebo arm inside this analysis. Only tirzepatide-treated participants were included. So “clinically meaningful” here is measured against where people started, not against an untreated comparison. Hold that distinction whenever a result is reported as change from baseline.

## The money version of the question

If you are budgeting for treatment, the [six-month cost tool](https://buythisglp.com/tools/six-month-cost) can show how recurring charges add up. The trial averages cannot tell you how much weight you would lose over the same period.

Studies of [how long people stay on treatment](https://buythisglp.com/research/how-long-do-people-stay-on-a-glp1) describe what happens in routine care. A separate [study of persistence when treatment was free](https://buythisglp.com/research/glp1-persistence-when-free) shows why price is only one part of that question. Ask your prescriber how to interpret your own progress.

## Frequently asked

How long before a GLP-1 starts working?

A post hoc analysis of 2,384 tirzepatide-treated participants sorted them by whether they had lost 5% of body weight by then, and followed both groups to week 72.

What if you have lost nothing after two months?

The groups that lost less than 5% at week 8 averaged 14.6% weight loss in SURMOUNT-1 and 10.8% in SURMOUNT-2 at week 72. Discuss your own progress and any treatment changes with your prescriber.

Does feeling sick mean it is working?

The analysis found similar patterns of gastrointestinal side effects across groups. It did not test whether nausea predicts weight loss for an individual.

What did the 12-month observational study find?

In a cohort of 14,046 US adults in routine care, mean twelve-month weight change was -13.0% on tirzepatide and -5.9% on semaglutide, with older GLP-1 drugs near -4.0%.

## Sources

1.  \[1\] Kokkinos A, et al. (2026). Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials Diabetes, Obesity and Metabolism. [PMID 42348366](https://pubmed.ncbi.nlm.nih.gov/42348366/)
2.  \[2\] Hwang I, Lee SW, Kim Y (2026). Real-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study Drug Design, Development and Therapy. [PMID 42518911](https://pubmed.ncbi.nlm.nih.gov/42518911/)
3.  \[3\] Venkatakrishnan AJ, Murugadoss K, Soundararajan V (2026). Decoding the hallmarks of GLP-1RA weight-loss super-responders Biology Methods & Protocols. [PMID 42147968](https://pubmed.ncbi.nlm.nih.gov/42147968/)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
